Moderna, Inc Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 7/12/2026)
| Balance Sheet | Total Assets | 12,338,000,000.00 | ROE | 70.11 % |
| Balance Sheet | Total Equity | 8,650,000,000.00 | ROA | -22.87 % |
| Cashflow | Capital Expenditures | -202,000,000.00 | P/FCF | -42.63 |
| Cashflow | Free Cash Flow | -2,064,999,936.00 | – | – |
| Cashflow | Operating Cash Flow | -1,873,000,000.00 | P/CF | -47.00 |
| Income | Earnings per Share (diluted) | -7.26 | Div. Yield | – |
| Income | Net Income | -2,822,000,000.00 | P/E | -31.21 |
| Income | Shares Outstanding | 389,000,000.00 | P/B | 10.18 |
| Income | Total Revenue | 1,944,000,000.00 | P/S | 45.28 |
Ratios calculated on: 10/14/2026
Company Description
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.modernatx.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more